Vol. 6, Issue 1, 2022March 17, 2022 CDT
Immunotherapy using CRISPR-Cas9 systems to treat rheumatoid arthritis with PTPN22 R620W mutations and target PD-1 and CD20
Immunotherapy using CRISPR-Cas9 systems to treat rheumatoid arthritis with PTPN22 R620W mutations and target PD-1 and CD20
Shivaraman, Aishwarya, and Nicole Guilz. 2022. “Immunotherapy Using CRISPR-Cas9 Systems to Treat Rheumatoid Arthritis with PTPN22 R620W Mutations and Target PD-1 and CD20.” Journal of High School Science 6 (1). https://doi.org/10.64336/001c.33705.